Dr. Leone is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215- Is this information wrong?
Summary
- Dr. Jose Leone is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute and Brigham and Women's Hospital. He received his medical degree from University of Salvador Faculty of Medicine and has been in practice 12 years. He also speaks multiple languages, including Spanish. He specializes in breast cancer and hematologic oncology and is experienced in male breast cancer.
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2011 - 2014
University of Miami/Jackson Health SystemResidency, Internal Medicine, 2008 - 2011
Univ Salvador- Fac MedClass of 2005
Certifications & Licensure
MA State Medical License 2017 - 2024
IA State Medical License 2014 - 2018
PA State Medical License 2011 - 2014- American Board of Internal Medicine Medical Oncology
Clinical Trials
- GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases Start of enrollment: 2019 Feb 11
- Tucatinib + Abemaciclib + Herceptin for HER2+ MBC Start of enrollment: 2020 Jun 28
- ETHAN - ET for Male BC Start of enrollment: 2023 Oct 11
Roles: Contact, Sponsor-Investigator, Principal Investigator
Publications & Presentations
PubMed
- Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer.Julieta Leone, Carlos T Vallejo, Olga Martínez-Sáez, Nabihah Tayob, Paolo Tarantino, Rachel A Freedman, Adrienne G Waks, Ana Garrido-Castro, Filipa Lynce, Nancy U Lin,...> ;NPJ Breast Cancer. 2024 Apr 4
- Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG).Carolien P Schröder, Elise van Leeuwen-Stok, Fatima Cardoso, Barbro Linderholm, Coralie Poncet, Antonio C Wolff, Vesna Bjelic-Radisic, Gustavo Werutsky, Miguel H Abreu...> ;The Oncologist. 2023 Oct 3
- The role of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.Jorge Avila, José Pablo Leone> ;Annals of Translational Medicine. 2023 Jan 15
- Join now to see all
Lectures
- Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry.2019 ASCO Annual Meeting - 6/1/2019
- Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses.2019 ASCO Annual Meeting - 6/1/2019
- A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Clinical Challenges: Diagnosing and Treating Male Breast CancerDecember 29th, 2022- The Pink Ribbon of Breast Cancer Awareness Needs a Splash of Blue for MenOctober 28th, 2023
Professional Memberships
- Member
Other Languages
- Spanish
Hospital Affiliations
Dana-Farber Cancer InstituteBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
